ImmuCell Announces Selection of its Next President and CEO

Core Viewpoint - ImmuCell Corporation has appointed Olivier te Boekhorst as the new President and CEO, effective November 1, 2025, to drive growth in its product offerings, particularly First Defense and Re-Tain [1][3]. Company Leadership Transition - Olivier te Boekhorst is currently an Operating Partner at ARCHIMED and has extensive experience in the animal healthcare sector, including leadership roles at IDEXX Laboratories [2]. - The current President and CEO, Michael F. Brigham, will transition to a Special Advisor role for at least two months to ensure a smooth leadership change [3]. Strategic Focus - The company aims to enhance sales of First Defense and advance the development of Re-Tain, which addresses animal health issues without traditional antibiotics [3]. - Mr. te Boekhorst emphasized the opportunity to improve farm animal welfare and sustainability in the dairy and beef industries [3]. Compensation Structure - Mr. te Boekhorst's employment terms include two stock option awards: one for 76,673 shares, granted on September 16, 2025, and a second award for up to 85,000 shares, to be granted after his employment begins [4]. - The stock options will have a 10-year term and will vest in three equal increments over three years [4]. Company Overview - ImmuCell Corporation focuses on developing products that improve the health and productivity of dairy and beef cattle, including First Defense for newborn calves and Re-Tain for mastitis treatment [6].